Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag

Hanahan, 1996, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 86, 353, 10.1016/S0092-8674(00)80108-7 Carmeliet, 2000, Angiogenesis in cancer and other diseases, Nature, 407, 249, 10.1038/35025220 Chambers, 2002, Dissemination and growth of cancer cells in metastatic sites, Nat Rev Cancer, 2, 563, 10.1038/nrc865 Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108 Folkman, 1972, Anti-angiogenesis: new concept for therapy of solid tumors, Ann Surg, 175, 409, 10.1097/00000658-197203000-00014 De Wever, 2003, Role of tissue stroma in cancer cell invasion, J Pathol, 200, 429, 10.1002/path.1398 Huang, 2002, Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein, Cancer Res, 62, 5727 Drevs, 2002, PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging, Cancer Res, 62, 4015 Huang, 2003, Regression of established tumors and metastases by potent vascular endothelial growth factor blockade, Proc Natl Acad Sci USA, 100, 7785, 10.1073/pnas.1432908100 Jeffes, 2005, Antiangiogenic drugs synergize with a membrane macrophage colony-stimulating factor-based tumor vaccine to therapeutically treat rats with an established malignant intracranial glioma, J Immunol, 174, 2533, 10.4049/jimmunol.174.5.2533 Xiang, 2005, A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication, Cancer Res, 65, 553 Morgan, 2003, J Clin Oncol, 21, 3955, 10.1200/JCO.2003.08.092 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Motzer RJ, Rini BI, Michaelson MD. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase II trial. J Clin Oncol, 2004. ASCO Annual Meeting. Proceedings (Post Meeting Edition). 2004:22:145 (July 15 Suppl). Willett, 2004, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer, Nat Med, 10, 145, 10.1038/nm988 Wei, 2000, Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine, Nat Med, 6, 1160, 10.1038/80506 Wei, 2001, Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen, Proc Natl Acad Sci USA, 98, 11545, 10.1073/pnas.191112198 Li, 2002, Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis, J Exp Med, 195, 1575, 10.1084/jem.20020072 Niethammer, 2002, A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth, Nat Med, 8, 1369, 10.1038/nm1202-794 He, 2003, Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice, J Biol Chem, 278, 21831, 10.1074/jbc.M300880200 Venanzi FM (2002), Stable A, Papa S, et al. Effect of immunoprevention of neu transgenic breast cancer by targeting both cancer and endothelial cells. : AACR Annual Meeting, 2002 April 6–10, San Francisco, CA. Proceeding of the American ssociation for Cancer Research; 43:90, abstract 448. St Croix, 2000, Genes expressed in human tumor endothelium, Science, 289, 1197, 10.1126/science.289.5482.1197 Rmali, 2005, Prognostic values of tumor endothelial markers in patients with colorectal cancer, World J Gastroenterol, 11, 1283, 10.3748/wjg.v11.i9.1283 Carson-Walter, 2001, Cell surface tumor endothelial markers are conserved in mice and humans, Cancer Res, 61, 6649 Nanda, 2004, TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI), Cancer Res, 64, 817, 10.1158/0008-5472.CAN-03-2408 Hotchkiss, 2005, TEM8 expression stimulates endothelial cell adhesion and migration by regulating cell–matrix interactions on collagen, Exp Cell Res, 305, 133, 10.1016/j.yexcr.2004.12.025 Bradley, 2001, Identification of the cellular receptor for anthrax toxin, Nature, 414, 225, 10.1038/n35101999 Scobie, 2005, Interactions between anthrax toxin receptors and protective antigen, Curr Opin Microbiol, 8, 106, 10.1016/j.mib.2004.12.005 Bonuccelli, 2005, ATR/TEM8 is highly expressed in epithelial cells lining Bacillus anthracis’ three sites of entry: implications for the pathogenesis of anthrax infection, Am J Physiol Cell Physiol, 288, C1402, 10.1152/ajpcell.00582.2004 Armstrong, 2005, Advanced prostate cancer: the future, Can J Urol, 12, 42 Todorova, 2005, Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded, Cancer Immun, 5, 1 Kinoshita, 2006, Expression of prostate-specific membrane antigen in normal and malignant human tissues, World J Surg, 30, 628, 10.1007/s00268-005-0544-5 Mincheff, 2006, Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals, Cancer Gene Ther, 13, 436, 10.1038/sj.cgt.7700914 Chianese-Bullock, 2005, Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2, J Immunother, 28, 412, 10.1097/01.cji.0000171314.00924.2b Dudley, 2002, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, 298, 850, 10.1126/science.1076514 Amici, 1998, Genetic immunization against neu/erbB2 transgenic breast cancer, Cancer Immunol Immunother, 47, 183, 10.1007/s002620050519 Naftzger, 1996, Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity, Proc Natl Acad Sci USA, 93, 14809, 10.1073/pnas.93.25.14809 Weber, 1998, Tumor immunity and autoimmunity induced by immunization with homologous DNA, J Clin Invest, 102, 1258, 10.1172/JCI4004 Bowne, 1999, Coupling and uncoupling of tumor immunity and autoimmunity, J Exp Med, 190, 1717, 10.1084/jem.190.11.1717 Gold, 2003, A single heteroclitic epitope determines cancer immunity following xenogeneic DNA immunization against a tumor differentiation antigen, J Immunol, 170, 5188, 10.4049/jimmunol.170.10.5188 Muller, 1988, Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene, Cell, 54, 105, 10.1016/0092-8674(88)90184-5 Nanni, 2000, p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma, Int J Cancer, 87, 186, 10.1002/1097-0215(20000715)87:2<186::AID-IJC5>3.0.CO;2-1 Hara, 1995, Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein, J Exp Med, 182, 1609, 10.1084/jem.182.5.1609 Ross, 1997, Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization, Clin Cancer Res, 3, 2191 Dyall, 1998, Heteroclitic immunization induces tumor immunity, J Exp Med, 188, 1553, 10.1084/jem.188.9.1553 Hawkins, 2000, Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity, Surgery, 128, 273, 10.1067/msy.2000.107421 Herr, 1996, Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens, J Immunol Methods, 191, 131, 10.1016/0022-1759(96)00007-5 Esserman, 1999, Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice, Cancer Immunol Immunother, 47, 337, 10.1007/s002620050539 Piechocki, 2001, Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2, J Immunol, 167, 3367, 10.4049/jimmunol.167.6.3367 Foy, 2001, Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor, Vaccine, 19, 2598, 10.1016/S0264-410X(00)00493-X Quaglino, 2004, Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice, Cancer Res, 64, 2858, 10.1158/0008-5472.CAN-03-2962 Chen, 1998, DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors, Cancer Res, 58, 1965 Pilon, 2001, Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody, J Immunol, 167, 3201, 10.4049/jimmunol.167.6.3201 Disis, 2003, Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens, Immunobiology, 207, 179, 10.1078/0171-2985-00230 Croci, 2004, Immunological prevention of a multigene cancer syndrome, Cancer Res, 64, 8428, 10.1158/0008-5472.CAN-04-2341 Lin, 2004, Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu, Mol Ther, 10, 290, 10.1016/j.ymthe.2004.05.015 Spadaro, 2005, Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant Interleukin-12) and adaptive (DNA vaccine electroporation) immunity, Clin Cancer Res, 11, 1941, 10.1158/1078-0432.CCR-04-1873 Perales, 2002, Strategies to overcome immune ignorance and tolerance, Semin Cancer Biol, 12, 63, 10.1006/scbi.2001.0397 Nair, 2003, Synergy between tumor immunotherapy and antiangiogenic therapy, Blood, 102, 964, 10.1182/blood-2002-12-3738